Embed Size (px)
DESCRIPTION
Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules.TechNavio's analysts forecast the Global Antisense and RNAi Therapeutics market to grow at a CAGR of 26.79 percent over the period 2014-2019.
Citation preview
Global Antisense and RNAi Therapeutics Market 2015-2019
TechNavio Insights
USA – CANADA – UK – CHINA – INDIA
Market Overview: Antisense and RNAi Therapeutics
About Antisense and RNAi Therapeutics • Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious
chronic and rare diseases.
• RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules.
• Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site on pre-mRNA and inactivates it effectively.
• RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics.
• RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi technology: miRNA and siRNA.
• TechNavio's analysts forecast the Global Antisense and RNAi Therapeutics market to grow at a CAGR of 26.79 percent over the period 2014-2019.
USA – CANADA – UK – CHINA – INDIA
Covered in This Report• This report covers the present scenario and the growth prospects of the Global Antisense and RNAi Therapeutics market for the period
2015-2019.
• To calculate the market size, the report considers the revenue generated from the sales of antisense and RNAi therapeutics used for the treatment of various serious chronic diseases including:
• Infectious diseases • Cardiovascular diseases • Kidney diseases • Cancer • Metabolic disorders • Others
• The report also covers the two main technologies, i.e., Antisense and RNAi technology, which are used by vendors to develop antisense and RNAi therapeutics.
• TechNavio's report, the Global Antisense and RNAi Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.
• The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Antisense and RNAi Therapeutics market landscape and its growth prospects in the coming years.
• The report also includes a discussion of the key vendors operating in this market.
USA – CANADA – UK – CHINA – INDIA
Key Regions
EMEA
Americas
APAC
USA – CANADA – UK – CHINA – INDIA
Key Vendors
Key Vendors• Alnylam Pharmaceuticals• Isis Pharmaceuticals• Sanofi• Tekmira Pharmaceuticals
Other Prominent Vendors• Acuitas Therapeutics• Allergan• Antisense Therapeutics• Ascletis• AstraZeneca• Atlantic Pharmaceuticals• Benitec Biopharma• Biogen Idec• Bristol-Myers Squibb• Dainippon Sumitomo Pharma• Dicerna Pharmaceuticals• Enzon Pharmaceuticals• F. Hoffmann-La Roche• Glaxosmithkline
USA – CANADA – UK – CHINA – INDIA
Market Drivers, Challenges and Trends
Guest BloggersDriver• Advances in Technology.• For a full, detailed list, view our report.
Challenge• Toxicity of Antisense and RNAi Molecules-based
Drugs.• For a full, detailed list, view our report.
Trend• Increased Strategic Collaborations and Licensing
Activities.• For a full, detailed list, view our report.
A detailed analysis of each market driver, challenge and
trend is available in our report:
Global Antisense and RNAi
Therapeutics Market 2015-2019
USA – CANADA – UK – CHINA – INDIA
Key Questions
Questions Answered in Our Report• What will the market size be in 2018 and what will the growth rate be?• What are the key market trends?• What is driving this market?• What are the challenges to market growth?• Who are the key vendors in this market space?• What are the market opportunities and threats faced by the key
vendors?• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
USA – CANADA – UK – CHINA – INDIA
View Our Report
Global Antisense and RNAi Therapeutics Market 2015-2019
View Report >>
TechNavio's report, Global Antisense and RNAi Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.
Published on: November 12, 2014 | 72 Pages | SKU: IRTNTR4600
USA – CANADA – UK – CHINA – INDIA
Access the Report
USA – CANADA – UK – CHINA – INDIA
India: An Overview
USA – CANADA – UK – CHINA – INDIA
About Us
USA – CANADA – UK – CHINA – INDIA
Thank You!
North America
Chicago, USA
Phone: +1 630 333 9501
Fax: +1 630 833 2171
Europe
London, United Kingdom
Phone: +44 208 123 1770
Fax: +44 845 280 2825
Asia
Bangalore, India
Phone: +91 934 254 0560
Fax: +91 80 4080 6070
Mail us at: [email protected]
You can visit us at:www.technavio.com
DISCLAIMER
This presentation is intended solely for showcasing Infiniti’s research capabilities. All information contained within this presentation has been randomized and should not be used for any kind of analysis and/or for decision making purpose. All trademarks and copyrights remain the sole ownership of their rightful owners/licensees. In no event shall Infiniti Research have any liability to any party for special, incidental, tort, or consequential damages arising out of
or in connection with this report, even if Infiniti Research has been advised of the possibility of such damages.
Copyright ©2013 Infiniti Research Limited. All Rights Reserved.
Reproduction without written permission is completely forbidden.
NOT FOR FURTHER DISTRIBUTION
![o m d i c i n e & Biotherape Journal of Nanomedicine & n ut a ic f o … · 2019. 4. 26. · RNA interference (RNAi) therapeutics [1,2]. RNA interference (RNAi) has emerged as an](https://img.pdfslide.us/doc/110x75/60bd07228e28df412574b9b3/o-m-d-i-c-i-n-e-biotherape-journal-of-nanomedicine-n-ut-a-ic-f-o-2019.jpg)
